EUCTR2011-005677-23-RO进行中（未招募）不适用
A two-year, double-blind, randomized, multicenter, active controlledstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon ß-1a i.m. once weekly in pediatric patients with multiple sclerosis
ovartis Pharma Service AG0 个研究点目标入组 190 人开始时间: 2014年5月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent must be obtained before any assessment is performed.
- •2. Male and female patients aged 10-17 years old, inclusive (i.e., have not yet had their 18th birthday) at randomization.
- •3. A diagnosis of MS as defined by the revised consensus definition for pediatric MS (Krupp et al 2013, Polman et al 2011).
- •- Central review of the diagnosis of pediatric MS will be required for all patients prior to randomization.
- •4. At least one MS relapse during the previous year or two MS relapses in the previous two years, preceding enrollment to the study.
- •5. Expanded Disability Status Scale (EDSS) score of 0 to 5.5, inclusive.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 190
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with progressive MS.
- •2. Patients with an active, chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g. Sjögren’s disease, systemic lupus erythematosus) or with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency) or tested positive for HIV.
- •3. Patients with widespread and symmetric white matter alterations in the Screening MRI suggestive of other demyelinating disorders (e.g. metabolic disorders, mitochondrial disorders).
- •4. Patients meeting the definition of ADEM (Krupp et al 2013); patients meeting critieria for neuromyelitis optica (Wingerchuk et al 2006) or tested positive for aquaporin 4 (AQP4) at Screening.
- •5. Patients who have detectable antibodies to IFN ß at Screening.
- •6. Patients treated with:
- •o Systemic corticosteroids or adrenocorticotropic hormone (ACTH) in the 30 days prior to Screening MRI scan
- •o High dose intravenous immunoglobulin within 2 months prior to randomization
- •o Natalizumab within 3 months prior to randomization
- •o Immunosuppressive/immunomodulatory medications such as cladribine, cyclophosphamide, mitoxantrone, azathioprine, methotrexate, rituximab, ofatumumab, ocrelizumab, alemtuzumab, teriflunomide or dimethyl fumarate at any time
- •o The following antiarrhythmic drugs at Screening: Class Ia (e.g. quinidine, disopyramide) or Class III (e.g. amiodarone, sotalol) anti-arrhythmics
- •o Concurrently treated with heart-rate-lowering drugs at Screening e.g.: Beta blockers, heart-rate lowering calcium channel blockers (e.g. verapamil, diltiazem or ivabradine), digoxin, anticholinesteratic agents, pilocarpine.
- •Advice from a cardiologist should be sought regarding the switch to non-heartrate lowering medicinal products.
- •7. Patients diagnosed with macular edema during the pre-randomization phase.
- •8. Patients with active systemic bacterial, viral or fungal infections, including tuberculosis.
- •9. Patients who have not completed their vaccination schedule based on the local recommendations.
- •10. Patients who are negative for varicella-zoster virus, mumps, measles, or rubella, diphtheria, tetanus or pertussis IgG antibodies at Screening.
- •11. Patients who have received any live or live attenuated vaccines (including for varicella-zoster virus or measles) within one month prior to randomization.
- •12. Patients with a history or presence of malignancy.
- •13. Patients with any medically unstable condition, as assessed by the primary treating physician at each site.
- •14. Patients with any severe cardiac disease or significant findings on the screening ECG, such as:
- •o History of symptomatic bradycardia or recurrent syncope
- •o Known ischaemic heart disease
- •o History of congenital heart disease (except conditions such as small patent ductus arteriosus, atrial septal defect, ventricular septal defect, or an ECG or rhythm abnormality, which have been assessed by a pediatric cardiologist and considered to be clinically insignificant).
- •o Cerebrovascular disease
- •o History of myocardial infarction
- •o Congestive heart failure
- •o History of cardiac arrest
- •o Uncontrolled hypertension despite prescribed medications
- •o Resting (sitting) heart rate <55 bpm (in patients 12 years or older) and <60 bpm (in patients below 12 years)
- •o Severe untreated sleep apnea.
- •o Sick sinus syndrome or sino-atrial heart block
- •o QTc interval >450 msec in males and >460 msec in females or relevant risk factors for QT prolongation (e.g. hy
研究者
相似试验
进行中（未招募）
不适用
Safety and efficacy of fingolimod in pediatric patients with multiple sclerosisEUCTR2011-005677-23-ITovartis Farma190
进行中（未招募）
1 期
Safety and efficacy of fingolimod in pediatric patients with multiple sclerosisRelapsing multiple sclerosisMedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disordersEUCTR2011-005677-23-GBovartis Pharma Service AG190
进行中（未招募）
不适用
Safety and efficacy of fingolimod in pediatric patients with multiple sclerosisEUCTR2011-005677-23-ESovartis Farmaceutica S.A.190
进行中（未招募）
1 期
Safety and efficacy of fingolimod in pediatric patients with multiple sclerosisRelapsing multiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-005677-23-SKovartis Pharma Services AG240
招募中
1 期
A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon ß-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension PhaseMultiple SclerosisCTIS2023-507556-68-00ovartis Pharma AG41